Skip to content
Screener

Alumis Inc. ALMS Q2 2026 earnings

Reported August 13, 2026 · After market close

Revenue$1.7MMiss by $2.0M
EPS-$1.11Miss by $0.34
Revenue estimate$3.7M
EPS estimate-$0.77
“Envudeucitinib's Phase 3 clinical validation in PsO, reinforced by our ONWARD3 long-term data, demonstrates the power of maximal TYK2 inhibition in IL-23/IL-17-driven diseases, and our anticipated Phase 2b LUMUS readout in SLE may substantiate its role in IFN-driven diseases -- potentially unlocking broader potential of our TYK2 franchise. The ONWARD3 long-term data delivered the highest reported PASI 100 response rate among oral therapies, positioning envudeucitinib to set a new standard in PsO. We remain on track to submit a New Drug Application for envudeucitinib in moderate-to-severe plaque psoriasis in Q4 with the goal, if approved, of bringing this new oral treatment option to patients.”
Martin Babler

Next report

Nov 12, 2026 (in 2 months)
Revenue estimate$1.9M
EPS estimate-$0.73

Financials

Q2 2026

Income statement

See full
Revenue$1.7M-37.7%
Operating income-$148.9M-5.9%
Net income-$142.2M-340%
EPS (diluted)-$1.11-244%

Balance sheet

See full
Cash & equivalents$63.7M-58.0%
Total debt$36.4M-6.1%
Total equity$452.2M-6.8%
Total assets$560.6M-8.2%

Cash flow

See full
Operating cash flow-$81.5M+23.4%
CapEx$237.0K-61.5%
Free cash flow-$81.7M+23.6%

Valuation & ratios

Valuation

as of 08/27/26
See full
Market cap$3.06B+502%
Enterprise value$3.03B+668%
P/S413.3×—

Profitability

See full
Operating margin-6,204.4%—
Net margin-5,933.5%—
FCF margin-4,755.3%—

Returns & leverage

See full
Return on equity-93.6%—
Debt / equity0.1×0.0×
Current ratio6.7×+0.7×

Segments

By product

See full
Collaboration Revenue$1.7M-37.0%
License-—

By segment

See full
Single Reportable$1.7M-37.7%

FAQ

When did Alumis Inc. report Q2 2026 earnings?
Alumis Inc. (ALMS) reported Q2 2026 earnings on August 13, 2026 after market close.
What were Alumis Inc.'s Q2 2026 revenue and EPS?
Alumis Inc. reported revenue of $1.7M and eps of $-1.11 for Q2 2026.
Did Alumis Inc. beat estimates in Q2 2026?
Revenue missed the consensus estimate of $3.7M by $2.0M. EPS missed the consensus estimate of $-0.77 by $0.34.
How did Alumis Inc.'s Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 37.7% from $2.7M a year earlier and eps grew 5.1% from $-1.17.
Where can I find Alumis Inc.'s Q2 2026 SEC filings?
You can read the 8-K earnings release (0001104659-26-093353) and the 10-Q periodic report (0001847367-26-000018) directly on SEC EDGAR. The filing index links above go to sec.gov.